166 related articles for article (PubMed ID: 25253883)
1. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
[TBL] [Abstract][Full Text] [Related]
2. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
3. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
[TBL] [Abstract][Full Text] [Related]
5. Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Coffey GP; Feng J; Betz A; Pandey A; Birrell M; Leeds JM; Der K; Kadri S; Lu P; Segal J; Wang YL; Michelson G; Curnutte JT; Conley PB
Clin Cancer Res; 2019 Feb; 25(4):1174-1184. PubMed ID: 30333224
[TBL] [Abstract][Full Text] [Related]
6. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.
Gillooly KM; Pattoli MA; Taylor TL; Chen L; Cheng L; Gregor KR; Whitney GS; Susulic V; Watterson SH; Kempson J; Pitts WJ; Booth-Lute H; Yang G; Davies P; Kukral DW; Strnad J; McIntyre KW; Darienzo CJ; Salter-Cid L; Yang Z; Wang-Iverson DB; Burke JR
J Pharmacol Exp Ther; 2009 Nov; 331(2):349-60. PubMed ID: 19652024
[TBL] [Abstract][Full Text] [Related]
7. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
8. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H
J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
[TBL] [Abstract][Full Text] [Related]
9. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
[TBL] [Abstract][Full Text] [Related]
10. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
[TBL] [Abstract][Full Text] [Related]
11. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
[TBL] [Abstract][Full Text] [Related]
12. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
13. JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.
Kato T; Ohta T; Iwasaki H; Kobayashi H; Matsuo A; Hata T; Matsushita M
Life Sci; 2017 Dec; 191():166-174. PubMed ID: 29056373
[TBL] [Abstract][Full Text] [Related]
14. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers.
Coffey G; Rani A; Betz A; Pak Y; Haberstock-Debic H; Pandey A; Hollenbach S; Gretler DD; Mant T; Jurcevic S; Sinha U
J Clin Pharmacol; 2017 Feb; 57(2):194-210. PubMed ID: 27406873
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.
Hoemann M; Wilson N; Argiriadi M; Banach D; Burchat A; Calderwood D; Clapham B; Cox P; Duignan DB; Konopacki D; Somal G; Vasudevan A
Bioorg Med Chem Lett; 2016 Nov; 26(22):5562-5567. PubMed ID: 27789138
[TBL] [Abstract][Full Text] [Related]
17. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
Das J; Chen P; Norris D; Padmanabha R; Lin J; Moquin RV; Shen Z; Cook LS; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; McIntyre KW; Shuster DJ; Gillooly KM; Behnia K; Schieven GL; Wityak J; Barrish JC
J Med Chem; 2006 Nov; 49(23):6819-32. PubMed ID: 17154512
[TBL] [Abstract][Full Text] [Related]
18. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.
Balsas P; Esteve-Arenys A; Roldán J; Jiménez L; Rodríguez V; Valero JG; Chamorro-Jorganes A; de la Bellacasa RP; Teixidó J; Matas-Céspedes A; Moros A; Martínez A; Campo E; Sáez-Borderías A; Borrell JI; Pérez-Galán P; Colomer D; Roué G
J Hematol Oncol; 2017 Mar; 10(1):80. PubMed ID: 28359287
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
20. Effect of AS2521780, a novel PKCθ selective inhibitor, on T cell-mediated immunity.
Fukahori H; Chida N; Maeda M; Tasaki M; Kawashima T; Matsuoka H; Suzuki K; Ishikawa T; Tanaka A; Higashi Y
Eur J Pharmacol; 2014 Dec; 745():217-22. PubMed ID: 25445039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
